CO2018007436A2 - Compuestos de dihidroquinolinsulfonamida de alquilo - Google Patents
Compuestos de dihidroquinolinsulfonamida de alquiloInfo
- Publication number
- CO2018007436A2 CO2018007436A2 CONC2018/0007436A CO2018007436A CO2018007436A2 CO 2018007436 A2 CO2018007436 A2 CO 2018007436A2 CO 2018007436 A CO2018007436 A CO 2018007436A CO 2018007436 A2 CO2018007436 A2 CO 2018007436A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- dihydroquinolinsulfonamide
- alkyl
- present
- itching
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de Fórmula I, I; y sales farmacéuticamente aceptables de estos, que son inhibidores de los canales de sodio activados por voltaje, en particular Nav1.7. Los compuestos son útiles para el tratamiento de enfermedades asociadas con la actividad de los canales de sodio tales como trastornos del dolor, tos y picazón. También se proporcionan composiciones farmacéuticas que contienen compuestos de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269518P | 2015-12-18 | 2015-12-18 | |
| PCT/US2016/067617 WO2017106871A1 (en) | 2015-12-18 | 2016-12-19 | Alkyl dihydroquinoline sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018007436A2 true CO2018007436A2 (es) | 2018-07-19 |
Family
ID=57758767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0007436A CO2018007436A2 (es) | 2015-12-18 | 2018-07-17 | Compuestos de dihidroquinolinsulfonamida de alquilo |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10383866B2 (es) |
| EP (1) | EP3390392B1 (es) |
| JP (1) | JP6903663B2 (es) |
| KR (1) | KR20180094946A (es) |
| CN (1) | CN108602804A (es) |
| AU (1) | AU2016369652B2 (es) |
| CA (1) | CA3008484C (es) |
| CL (1) | CL2018001631A1 (es) |
| CO (1) | CO2018007436A2 (es) |
| CR (1) | CR20180368A (es) |
| EA (1) | EA038286B1 (es) |
| IL (1) | IL259918B (es) |
| MA (1) | MA44065A (es) |
| MX (1) | MX2018007432A (es) |
| MY (1) | MY197595A (es) |
| NZ (1) | NZ743377A (es) |
| PE (1) | PE20181328A1 (es) |
| PH (1) | PH12018501285A1 (es) |
| SG (1) | SG11201805066RA (es) |
| TN (1) | TN2018000214A1 (es) |
| UA (1) | UA122913C2 (es) |
| WO (1) | WO2017106871A1 (es) |
| ZA (1) | ZA201804033B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物 |
| JP2021195368A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| AU2021288190A1 (en) | 2020-06-10 | 2022-12-22 | Amgen Inc. | Heteroalkyl dihydroquinoline sulfonamide compounds |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| MX2014001851A (es) * | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| EP2788332A1 (en) * | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| WO2014201173A1 (en) * | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-12-19 MY MYPI2018000912A patent/MY197595A/en unknown
- 2016-12-19 US US16/062,606 patent/US10383866B2/en active Active
- 2016-12-19 SG SG11201805066RA patent/SG11201805066RA/en unknown
- 2016-12-19 UA UAA201806895A patent/UA122913C2/uk unknown
- 2016-12-19 NZ NZ743377A patent/NZ743377A/en unknown
- 2016-12-19 MX MX2018007432A patent/MX2018007432A/es active IP Right Grant
- 2016-12-19 MA MA044065A patent/MA44065A/fr unknown
- 2016-12-19 KR KR1020187019086A patent/KR20180094946A/ko unknown
- 2016-12-19 CN CN201680074274.2A patent/CN108602804A/zh active Pending
- 2016-12-19 EP EP16823447.4A patent/EP3390392B1/en active Active
- 2016-12-19 CR CR20180368A patent/CR20180368A/es unknown
- 2016-12-19 TN TNP/2018/000214A patent/TN2018000214A1/en unknown
- 2016-12-19 EA EA201891319A patent/EA038286B1/ru unknown
- 2016-12-19 JP JP2018531483A patent/JP6903663B2/ja active Active
- 2016-12-19 PE PE2018001136A patent/PE20181328A1/es unknown
- 2016-12-19 CA CA3008484A patent/CA3008484C/en active Active
- 2016-12-19 WO PCT/US2016/067617 patent/WO2017106871A1/en active Application Filing
- 2016-12-19 AU AU2016369652A patent/AU2016369652B2/en active Active
-
2018
- 2018-06-10 IL IL259918A patent/IL259918B/en active IP Right Grant
- 2018-06-14 PH PH12018501285A patent/PH12018501285A1/en unknown
- 2018-06-15 CL CL2018001631A patent/CL2018001631A1/es unknown
- 2018-06-15 ZA ZA2018/04033A patent/ZA201804033B/en unknown
- 2018-07-17 CO CONC2018/0007436A patent/CO2018007436A2/es unknown
-
2019
- 2019-07-12 US US16/510,816 patent/US20200009129A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3390392A1 (en) | 2018-10-24 |
| MA44065A (fr) | 2021-05-26 |
| EP3390392B1 (en) | 2021-10-06 |
| IL259918A (en) | 2018-07-31 |
| CL2018001631A1 (es) | 2018-09-28 |
| AU2016369652B2 (en) | 2020-10-22 |
| CR20180368A (es) | 2018-09-28 |
| BR112018012298A2 (pt) | 2018-12-04 |
| NZ743377A (en) | 2022-05-27 |
| WO2017106871A1 (en) | 2017-06-22 |
| MY197595A (en) | 2023-06-27 |
| JP6903663B2 (ja) | 2021-07-14 |
| EA201891319A1 (ru) | 2018-11-30 |
| US20200009129A1 (en) | 2020-01-09 |
| PE20181328A1 (es) | 2018-08-20 |
| CN108602804A (zh) | 2018-09-28 |
| PH12018501285A1 (en) | 2019-02-04 |
| EA038286B1 (ru) | 2021-08-04 |
| IL259918B (en) | 2020-06-30 |
| JP2019504016A (ja) | 2019-02-14 |
| CA3008484A1 (en) | 2017-06-22 |
| AU2016369652A1 (en) | 2018-06-28 |
| KR20180094946A (ko) | 2018-08-24 |
| MX2018007432A (es) | 2018-09-21 |
| SG11201805066RA (en) | 2018-07-30 |
| US20180369227A1 (en) | 2018-12-27 |
| TN2018000214A1 (en) | 2019-10-04 |
| ZA201804033B (en) | 2019-04-24 |
| CA3008484C (en) | 2023-10-17 |
| US10383866B2 (en) | 2019-08-20 |
| UA122913C2 (uk) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
| CO2017009614A2 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| CR20180374A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| SV2016005311A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| SV2015005066A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| UY35288A (es) | Piridonamidas como moduladores de canales de sodio | |
| CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| CR20170092A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| CL2017002957A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| PE20160801A1 (es) | Derivados de heterobicicloaril como inhibidores rorc2 y metodos de uso de los mismos | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| CU20140107A7 (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| AR111416A2 (es) | Compuesto terapéutico para el dolor y síntesis del compuesto |